Christine Prodinger

Christine Prodinger

Auto-generated profile, based on publicly available information

Christine Prodinger

Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University Salzburg Austria

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
CPChristine Maria Prodinger
Christine Maria Prodinger
JKJosef Koller
Josef Koller
MLMartin Laimer
Martin Laimer

1 January 2017 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
CPChristine M. Prodinger
Christine M. Prodinger
JRJulia Reichelt
Julia Reichelt
JBJohann W. Bauer
Johann W. Bauer
MLMartin Laimer
Martin Laimer
Prodinger CM, et al. Ann Dermatol. 2017 Dec;29(6):667-687. https://doi.org/10.5021/ad.2017.29.6.667

13 September 2021 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
CPChristine Prodinger
Christine Prodinger
SCSubhanitthaya Chottianchaiwat
Subhanitthaya Chottianchaiwat
JMJemima E. Mellerio
Jemima E. Mellerio
JMJohn A. McGrath
John A. McGrath
LOLinda Ozoemena
Linda Ozoemena
AMAnna E. Martinez
Anna E. Martinez

10 July 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CPChristine Prodinger
Christine Prodinger
ADAnja Diem
Anja Diem
KUKatherina Ude-Schoder
Katherina Ude-Schoder
JPJosefina Piñón-Hofbauer
Josefina Piñón-Hofbauer
SKSophie Kitzmueller
Sophie Kitzmueller
MLMartin Laimer
Martin Laimer
Background: Epidermolysis bullosa (EB) comprises inherited mechanobullous dermatoses with considerable morbidity and mortality. While current treatments are symptomatic, a growing number of innovative therapeutic compounds are evaluated in clinical trials. Clinical research in rare diseases like EB, however, faces many challenges, including sample size requirements and recruitment failures. The objective of this study was to determine attitudes of EB patients towards clinical research and trial participation as well as the assessment of contextual motivating and discouraging factors in an effort to support patient-centered RD trial designing. Methods: A 53-items questionnaire was handed over to EB patients (of all types and ages) in contact with the EB House Austria, a designated national center of expertise for EB care. Main categories included level of interest in and personal knowledge about clinical studies, pros/cons for participation and extent of individual expenses considered acceptable for participation in a clinical study. Descriptive subgroup analysis was calculated with SPSS 20.0 and Microsoft Excel. Results: Thirty-six individuals (mean age 25.7 years), diagnosed for recessive dystrophic EB (36.1%), EB simplex (33.4%), junctional EB (8.3%), dominant dystrophic EB (2.8%) and acral peeling syndrome (2.8%) participated. Motivation for participation in and the desire to increase personal knowledge about clinical trials were (outmost) high in 57.2 and 66.7%, respectively. Altruism was the major motivating factor, followed by hope that alleviation of the own symptoms can be achieved. The greatest hurdle was travel distance, followed by concerns about possible adverse reactions. Patients diagnosed for severe subgroups (RDEB, JEB) were more impaired by the extent of scheduled invasive investigations and possible adverse reactions of the study medication. Patients with generally milder EB forms and older patients were accepting more frequent outpatient study visits, blood takes, skin biopsies and inpatient admissions in association with trial participation. Conclusions: This study provides additional indications to better determine and address attitudes towards clinical research among EB patients as well as guidance to improve clinical trial protocols for patient centricity.

1 December 2016 in Wiener klinische Wochenschrift
Verified
Journal Article
Open access
PDF file
MLMartin Laimer
Martin Laimer
GPGabriela Pohla-Gubo
Gabriela Pohla-Gubo
ADAnja Diem
Anja Diem
CPChristine Prodinger
Christine Prodinger
JBJohann W Bauer
Johann W Bauer
HHHelmut Hintner
Helmut Hintner
Accurately addressing the diverse and complex issues of rare diseases (RD) in terms of prevention, recognition, diagnosis, treatment, care and research along key RD specificities, such as great heterogeneity, a limited number of patients, scarcity of relevant knowledge and expertise as well as enormous costs for patient care is a challenging task for healthcare providers and authorities that makes a supranational approach particularly feasible. The European Union has acknowledged RD matters by several initiatives, including efforts to implement national centres of expertise and European reference networks as well as a cross-border referral mechanism to foster access to expert services and to boost dissemination of clinical expertise and research activities. Exemplified by the EB House Austria, a centre of expertise for epidermolysis bullosa cross-linked with international reference partner institutions, this strategy proves its potential to be translated into optimized patient care and to meet the major medical, scientific, social and health-economic impact of RD.

11 October 2020 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
CPChristine Prodinger
Christine Prodinger
JBJohann W Bauer
Johann W Bauer
MLMartin Laimer
Martin Laimer
Epidermolysis bullosa (EB) is the prototypical example of genetic skin fragility disorders. Genotypic heterogeneity, modifier genes, epigenetic, biochemical and environmental factors alter and determine pathogenic traits and, ultimately, the wide and striking phenotypic variability in EB. Besides the primary structural‐functional defect, chronic tissue damage with induction and dysregulation of inflammatory pathways is a common pathogenic mechanism in EB. In localized variants, the inflammatory aberrations may mainly affect the micromilieu of lesional skin, while a systemic inflammatory response was shown to contribute to the systemic morbidity in severe EB subtypes with extensive cutaneous involvement. Our continued understanding of the pathophysiology of EB, as well as advances in molecular technologies, has paved the way for translational therapeutic approaches. The spectrum comprises of corrective and symptom‐relieving therapies that include innovative therapeutic options garnered from the bench, repurposed drugs approved for other diseases, as well as strategies for gene‐, protein‐ and cell‐based therapies. Immunological traits further define new targets of therapy, aimed at improving skin barrier restoration, microbial surveillance and infection control, wound healing and anti‐neoplastic effects. Clinical availability and feasibility of these approaches for all EB patients and subtypes are currently limited, reflecting issues of efficacy, specificity, tolerability and safety. A multistep targeting approach and highly individualized, risk‐stratified combinatory treatment plans will thus be essential for sustained efficacy and improved overall quality of life in EB.